Have a personal or library account? Click to login

Figures & Tables

Table I

Schedule for Data Collection.

PrenatalBirth3m6m12m24m36m48m
Clinical Exam
Anthropometric×××××××
Physical Exam×××××××
NCPDTests1××××××
Biological Samples
Umbilical Cord Blood×
Meconium×
Tissue samples2×
Maternal milk××
Urine (child)××××××
Urine (mother)×
Blood (mother)×
Saliva (child)×××××××
Questionnaires
Gestation: 32nd week×
Birth×
Follow up×××××××

[i] 1 Neuromotor, cognitive and psychologic developmental tests; 2umbilical cord and placenta.

agh-86-1-2709-g1.png
Figure 1

Follow-up endpoints.

Table II

Environmental pollutants, types of sample and biological matrices.

Biologic MatrixEnvironmental PollutantsTypes of sample
Prenatal: 27th to 32nd week.
BloodMetals(1); Organochlorine pesticides; Bisphenol; Polychlorinated biphenyls (PCBs); Phthalates;Parents
UrineMetals(1) Pyrethroids; Bisphenol; Phthalates.Parents
Birth
Umbilical Cord BloodMetals(1) Organochlorine pesticides; Polychlorinated biphenyls (PCBs);Newborn
MeconiumMetals(1)Newborn
Postnatal until 4 years old
UrineMetals(1) Pyrethroids; Bisphenol; Phthalates.Newborn/infant/toddler
Maternal Milk (2)Metals(1) Organochlorine pesticides; Polychlorinated biphenyls (PCBs).Mother

[i] (1) Metals: Lead, Arsenic. Cadmium and Mercury.

(2) In the 3rd and 6th follow-up months.

Table III

Recruitment and participation in the PIPA Pilot Study.

  • Enrollment: October and November/2017 (2 months):

    All pregnant women that attended the Prenatal Maternity School Program/UFRJ: 209 were invited to participate: 142 (67.9%): agreed.

    Phase 1_PreNatal: 142 pregnant women, 139 (98%) collected blood, 142 (100%) urine and hair samples.

  • Phase 2_Birth: 135 (95, 1%) newborns: 126 (93%): collected umbilical cord blood samples; 54 (40%) collected urine samples; 117 (86.7%) collected meconium samples.

  • Phase 3_Follow-up: 130 eligible newborns: 77 (59%) returns (1st, 3rd or 6th months).

    A total of 177 newborns urine samples and 151 maternal milk samples were collected

Table IV

Comparison between the PIPA Pilot Study population data and Rio de Janeiro municipality population data.

Maternal CharacteristicsPIPA Pilot StudyMRJ*
%(N)%(N)
Maternal age (139)(1)15 to 19 years old8.6(12)13.9(11194)      
20 to 39 years old84.2(117)82.2(66024)      
Up to 40 years old7.2(10)3.9(3154)      
Years of Study (137)(1)Lower than 8 years of study7.3(10)1.5(13724)      
Higher than 8 years of study92.7(127)82.5(64494)      
Ethnicity (135)(1)White23.9(34)36.6(29057)      
Non-White71.1(101)63.4(50230)      
Newborn CharacteristicsPIPA Pilot StudyMRJ*
%(N)%(N)
GenderMale57.3(75)51.1(42,223)      
Female43.7(56)48.9(40,370)      
BirthWeight (1)**1.000–25009(12)8.6(7,143)      
2500–399982.7(110)86.2(71,224)      
> 40008.3(11)5.1(4,234)      
Birth Weight Adequacy for Gestational Age(1)***SGA9.2(11)9.3(165)****
AGA81.5(97)74.8(1,324)****
LGA9.2(11)15.9(282)****

[i] * MRJ: Rio de Janeiro Municipality. Source: MS Datasus/Sinasc–2016.

** Total PIPA number: 133 newborns; Total number RJ: 82.601 newborns.

*** Total PIPA number: 119 newborns.

**** Source: Kale et all, 2018 [25]; Total live births: 1,771; SGA: Small for the gestational age; AGA: adequate for the gestational age; LGA: large for the gestational age.

(1) Incomplete data on the specific covariates.

Table V

Metal levels in mother and umbilical cord blood – Pilot study.

MetalsSampleGeometric Mean (95% IC)MinMax
Pb (µg/dL)Mother blood3.74 (3.40–4.12)1.1115.26
Umbilical Cord Blood3.85 (3.53–4.19)1.4316.03
Hg (µg/L)Mother blood1.00 (0.85–1.18)0.3313.32
Umbilical Cord Blood1.11 (0.97–1.27)0.356.38
Cd (µg/L)Mother blood0.30 (0.29–0.53)0.00222.43
Umbilical Cord Blood0.41 (0.32–0.52)0.00417.41
As (µg/L)Mother blood10.27 (9.37–11.18)0.3336.48
Umbilical Cord Blood10.31 (9.75–10.93)4.8919.94

[i] Metal limits of detection: Pb 0.015 μg/L; Hg 0.007 μg/L; Cd 0.002 μg/L; As 0.003 μg/L.

Table VI

3BPA and 4FBA metabolite detection rates – Mother and child urine.

SamplesN analysed3PBA ng mL-1 Detection4FPBA Detection
NRateNRate
Mother Urine1406747.9%1410%
Urine newborn34823.5%00
Urine 1st follow up26519.2%00
Urine 2nd follow up501428%00
Urine 3rd follow up561221.4%00

[i] Metabolite limits of detection: 3BPA 0.06 ng mL–1; 4FPBA 0.05 ng mL–1.

Table VII

PIPA Project Risk Points and Responding Strategies.

Risk pointsResponding strategies
Management structure
Underestimating of research costsPermanent search for financial support
Careful evaluation of the Pilot Study
Underestimating number of required staff
High research assistant and interviewer turnover
Permanent hiring and training
Laboratory capacity underestimation
Absence of laboratorial capacity regarding some specific technical analyses
Searches for other laboratories with similar qualifications
Searches for international partnerships
Establishment of an infrastructure to attend and monitor the population during the cohort periodAccomplishment of alternative attendance schemes for using non-occupied periods
High local government decision makers turnoverDevelopment and maintenance of ongoing collaboration and information nets between the researchers, the maternity and family health center teams
Participant recruitment
Living far from Maternity: monetary displacement costsMonetary provision to help the participants with displacement costs to the Maternity School, during the follow-up period
No time to answer the questionnaire and to collect the biological samplesReview of the Enrollment questionnaire and Seminar dynamics to optimize data collection.
Maximize participant convenience: data collection efficiency; data collector flexibility.
Participant retention“Health, Environment and Child Development Educational Program”
Faults in the follow-up visitsOngoing sensibilization and contact
Establishment of a reliable liaison between the research team and project participants
Use of digital tools: social nets, PIPA website, interactive communication
Maintain communication: phone calls, messages.
Obtain other contact detail information;
Data CollectionDaily tracking of participants approaching due dates
Reminders through direct communication in each data
collection time-point
Rescheduling appointments
Ongoing interviewer training
Recruiting specialized teams to collect biological samples
Quality Assurance
Incompleteness of covariate dataRigorous information system infrastructure
Questionnaire information collected directly within the database system, using a single data entry with periodic response verification
Periodic data tracking and quality checks
Unanimous adaptation of pre-specified data collection and management protocols
Collecting data relating to numerous potential confounding variables
Careful control through statistical analyses
DOI: https://doi.org/10.5334/aogh.2709 | Journal eISSN: 2214-9996
Language: English
Published on: Jun 11, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2020 Carmen Ildes R. Fróes Asmus, Arnaldo Prata Barbosa, Armando Meyer, Nataly Damasceno, Ana Cristina Simões Rosa, Roberto Medronho, Antônio Jose Ledo A. da Cunha, Josino Costa Moreira, Thatiana V. R. de B. Fernandes, Marlos Martins, Ronir Raggio Luiz, Volney de Magalhães Câmara, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.